Abstract：
The 2019 coronavirus (COVID-19) pandemic raised many scientific and medical questions. Of interest are the duration and effectiveness of the humoral immune response, especially since part of the pandemic occurred in the presence of anti-SARS-CoV-2 vaccines. We retrospectively studied 564 serum samples from 393 post-infected and vaccinated individuals to investigate the longevity and magnitude of the anti-spike IgG response. Our results showed that SARS-CoV-2 anti-spike IgG antibodies are retained for nine-twelve months, in both groups. In the vaccinated group we found higher IgG levels, but with a steeper decrease in titer over the study period. The recovered group\'s antibody levels correlated well with the national infection trendline for 2021. Both groups showed different, but distinct neutralizing capabilities towards RBD. The anti-Spike IgG response was sustained and efficient, independently of the triggering event, infection or vaccination, with the adaptive capacity against new viral variants being more valuable after infection.
摘要：
2019年冠状病毒（COVID-19）大流行引发了许多科学和医学问题。感兴趣的是体液免疫反应的持续时间和有效性，特别是因为部分大流行发生在抗SARS-CoV-2疫苗的存在下。我们回顾性研究了来自393名感染后和接种疫苗的个体的564份血清样品，以研究抗峰IgG反应的寿命和程度。我们的结果表明，SARS-CoV-2抗刺IgG抗体保留9-12个月，在两组中。在接种组，我们发现更高的IgG水平，但在研究期间滴度急剧下降。恢复组的抗体水平与2021年的全国感染趋势线密切相关。两组显示不同，但对RBD具有明显的中和能力。抗-SpikeIgG应答持续有效,独立于触发事件，感染或疫苗接种，对新病毒变体的适应能力在感染后更有价值。
